NCT02016066View on ClinicalTrials.gov

A Study to Assess the Safety, Pharmacokinetics and Immunogenicity of CR6261 in Japanese Healthy Participants

PHASE1WithdrawnINTERVENTIONAL
0
Timeline

Start Date

December 31, 2013

Primary Completion Date

January 31, 2014

Study Completion Date

April 30, 2014

Conditions
Healthy
Interventions
DRUG

CR6261

CR6261 50 mg/kg solution will be administered as a single 2-hour intravenous infusion

DRUG

Placebo

Placebo will be administered as a single 2-hour intravenous infusion

Trial Locations (1)

Unknown

Osaka

Sponsors
All Listed Sponsors
lead

Janssen Pharmaceutical K.K.

INDUSTRY